Skip to content

A randomized, double-blind, placebo-controlled study of Danggui Shaoyao Powder in the treatment of patients with mild cognitive impairment

A randomized, double-blind, placebo-controlled study of Danggui Shaoyao Powder in the treatment of patients with mild cognitive impairment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026001120
Enrollment
Unknown
Registered
2026-04-28
Start date
2026-05-01
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild cognitive impairment

Interventions

Treatment group:Taking the Danggui Shaoyao Granules orally for 3 months
Placebo control group:Taking the Danggui Shaoyao Powder placebo orally for 3 months

Sponsors

Hunan Hospital of Integrated Traditional Chinese and Western Medicine(Affiliated Hospital of Hunan Provincial Institute of Traditional Chinese Medicine)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Age: 50 - 85 years old. 2.Diagnosis: After assessment by a doctor, it has been confirmed as forgotten type mild cognitive impairment (aMCI), and urine test shows positive for Aß. 3.TCM syndrome: Consistent with the TCM diagnosis of spleen deficiency and liver stagnation, with impaired blood circulation (common manifestations: forgetfulness, low mood, dizziness and lightheadedness, average appetite, loose stools, etc.). 4.Informed Consent: You, along with a family member who is familiar with your daily situation (the informed party), sign this consent form together.

Exclusion criteria

Exclusion criteria: 1.Has been diagnosed with dementia (such as Alzheimer's disease in the dementia stage, vascular dementia, etc.). 2.Has severe mental disorders such as depression and schizophrenia that are not under control. 3.Has severe dysfunction of the heart, liver, and kidneys. 4.Has taken drugs for treating dementia in the elderly (such as donepezil, memantine, etc.) within the last 3 months. Brain magnetic resonance (MRI) shows large areas of cerebral infarction, brain tumors, etc.

Design outcomes

Primary

MeasureTime frame
Clinical Dementia Rating;

Secondary

MeasureTime frame
Montreal Cognitive Assessment;Auditory Verbal Learning Test-Huashan Version;Functional Activites Questionnair;Urine Aß42;Traditional Chinese Medicine Syndrome Score;

Countries

China

Contacts

Public ContactYa-Han Wang

Hunan Hospital of Integrated Traditional Chinese and Western Medicine(Affiliated Hospital of Hunan Provincial Institute of Traditional Chinese Medicine)

wyahan621@outlook.com15811105935

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Jun 11, 2026